Key Highlights
- ADMA Biologics, Inc. (NASDAQ:ADMA) traded 25.52% higher at USD 13.16 in trading on November 5, 2026, per published market data, on Volume of 3.37 million shares.
- Third quarter 2026 Revenue was USD 141.1 million, up 5%, while ASCENIV revenue rose 31% to USD 124.7 million.
- GAAP Net Income climbed 37% to USD 49.9 million and adjusted EBITDA rose 32% to USD 77.3 million.
- Guidance now calls for adjusted net income of at least USD 180 million and adjusted EBITDA of at least USD 275 million for 2026.
Third Quarter Results and Higher Profit Targets
ADMA Biologics, Inc. (NASDAQ:ADMA) released third quarter 2026 results on November 4, 2026, and the stock rallied the next session. In trading on November 5, 2026, per published market data, the shares were quoted at USD 13.16, up 25.52%, with a Market Value near USD 2.95 billion, trailing diluted Earnings of USD 0.70 per share and a price-to-earnings multiple of 18.67. Revenue was USD 141.1 million, up 5%. ASCENIV, the company's immune globulin for primary immunodeficiency, generated USD 124.7 million, up 31%. GAAP net income reached USD 49.9 million, up 37%, and adjusted EBITDA of USD 77.3 million was 32% higher. The company raised its adjusted net income and adjusted EBITDA guidance and reiterated revenue of at least USD 530 million.
Mix Shift, Buybacks and Balance Sheet
Profit grew much faster than revenue because the sales mix moved toward ASCENIV, which commands higher pricing, while BIVIGAM, an older immune globulin, fell 35% to USD 15.4 million. Adjusted EBITDA, which excludes interest, taxes, Depreciation and certain non-cash items, is the figure management uses to show operating earning power. The company repurchased 2.7 million shares in the quarter and 16.5 million shares year to date, about 6.3% of the shares outstanding at December 31, 2025, and says it is on track to meet its target of USD 200 million or more of repurchases in 2026. Chief executive Adam Grossman said the company is turning accelerating ASCENIV Demand into substantial earnings growth. Cash was USD 124.6 million, against USD 87.6 million at year-end 2025.
Debt, Concentration and Reversal Risks
Long-term Debt was USD 191.6 million plus a USD 4.2 million current portion, about USD 195.9 million in total on simple arithmetic, compared with roughly USD 72.1 million at the end of 2025, so repurchases have been partly funded with borrowing. ADMA Biologics, Inc. (NASDAQ:ADMA) depends on ASCENIV for most of its sales, which raises exposure to competing immune globulin products, plasma Supply and reimbursement changes. The 35% fall at BIVIGAM shows how quickly a product can lose ground. Overall revenue growth of 5% is modest next to the size of the share price move, and the trailing earnings growth of negative 17.05% in published market data reflects a tougher comparison base. Gains of this size can retrace. Investors should watch ASCENIV trends, borrowing levels and the fourth quarter report.
Where Things Stand
The 25.52% rally at ADMA Biologics, Inc. (NASDAQ:ADMA) reflects reported strength: ASCENIV up 31%, net income up 37% and higher adjusted profit guidance. The reaction is sizable for revenue growth of only 5%, so the market is clearly paying for Margin expansion and buybacks rather than sales volume. Debt of about USD 195.9 million, reliance on one product and the BIVIGAM decline are the main counterweights. The next catalyst is the fourth quarter report and any update to the 2026 targets.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...